CL2017000309A1 - Indoles para su uso en la infección por el virus de la gripe - Google Patents

Indoles para su uso en la infección por el virus de la gripe

Info

Publication number
CL2017000309A1
CL2017000309A1 CL2017000309A CL2017000309A CL2017000309A1 CL 2017000309 A1 CL2017000309 A1 CL 2017000309A1 CL 2017000309 A CL2017000309 A CL 2017000309A CL 2017000309 A CL2017000309 A CL 2017000309A CL 2017000309 A1 CL2017000309 A1 CL 2017000309A1
Authority
CL
Chile
Prior art keywords
indoles
influenza virus
virus infection
flu
infection
Prior art date
Application number
CL2017000309A
Other languages
English (en)
Inventor
Gowan David Craig Mc
Pierre Jean-Marie Bernard Raboisson
Werner Constant Johan Embrechts
Tim Hugo Maria Jonckers
Jerôme Emile Georges Guillemont
Ludwig Paul Cooymans
Antoine Benjamin Michaut
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of CL2017000309A1 publication Critical patent/CL2017000309A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

<p>INDOLES PARA SU USO EN LA INFECCIÓN POR EL VIRUS DE LA GRIPE LA INVENCIÓN SE REFIERE A COMPUESTOS QUE TIENEN LA ESTRUCTURA DE FÓRMULA (1) QUE SE PUEDEN UTILIZAR PARA EL TRATAMIENTO DE INFECCIONES DE LA GRIPE O CONTRA ESTAS.</p>
CL2017000309A 2014-08-08 2017-02-07 Indoles para su uso en la infección por el virus de la gripe CL2017000309A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14180331 2014-08-08

Publications (1)

Publication Number Publication Date
CL2017000309A1 true CL2017000309A1 (es) 2017-08-18

Family

ID=51298610

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000309A CL2017000309A1 (es) 2014-08-08 2017-02-07 Indoles para su uso en la infección por el virus de la gripe

Country Status (18)

Country Link
US (1) US10597390B2 (es)
EP (1) EP3177609A1 (es)
JP (1) JP6577570B2 (es)
KR (1) KR102488479B1 (es)
CN (1) CN106573920B (es)
AU (1) AU2015298876B2 (es)
BR (1) BR112017002370B1 (es)
CA (1) CA2954751C (es)
CL (1) CL2017000309A1 (es)
EA (1) EA201790266A1 (es)
IL (1) IL250408B (es)
MA (1) MA40547A (es)
MX (1) MX2017001752A (es)
PH (1) PH12017500207B1 (es)
SG (1) SG11201700956VA (es)
UA (1) UA124609C2 (es)
WO (1) WO2016020526A1 (es)
ZA (1) ZA201700952B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3141252B8 (en) 2009-06-17 2019-03-13 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP3177609A1 (en) 2014-08-08 2017-06-14 Janssen Sciences Ireland UC Indoles for use in influenza virus infection
EP3294735B8 (en) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
WO2017097234A1 (en) 2015-12-09 2017-06-15 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
EA201891576A1 (ru) * 2016-01-07 2018-11-30 Янссен Сайенсиз Айрлэнд Юси Функционализированные пентановые кислоты для применения при инфекциях, вызванных вирусом гриппа
WO2017133670A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2018033082A1 (en) * 2016-08-16 2018-02-22 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
CN109641868B (zh) * 2016-08-30 2021-12-03 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
US11136319B2 (en) * 2016-09-05 2021-10-05 Guangdong Raynovent Biotech Co., Ltd. Anti-influenza virus pyrimidine derivative
WO2018108125A1 (en) 2016-12-15 2018-06-21 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
US11542233B2 (en) 2016-12-23 2023-01-03 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use
WO2018127096A1 (en) 2017-01-05 2018-07-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
CN110446711B (zh) 2017-03-02 2022-02-15 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
CN108727369B (zh) * 2017-04-25 2023-06-09 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
US11535613B2 (en) 2018-03-05 2022-12-27 Guangdong Raynovent Biotech Co., Ltd. Crystal form and salt form of pyridoimidazole compound and preparation method therefor
WO2021012864A1 (zh) * 2019-07-22 2021-01-28 广东众生睿创生物科技有限公司 嘧啶衍生物的优势盐型及其晶型
CN113045475A (zh) * 2019-12-27 2021-06-29 上海泓博智源医药股份有限公司 一种5-溴-7-甲基吲哚的制备方法
KR20230079003A (ko) 2020-07-20 2023-06-05 니도 바이오사이언시스, 인코포레이티드 안드로겐 수용체 조절제로서의 인돌 화합물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372624B (en) 2004-03-30 2012-09-21 Vertex Pharma Azaindoles useful as inhibitors of jak and other protein kinases
BRPI0722364A2 (pt) 2006-01-17 2011-08-16 Vertex Pharma azaindóis, composição farmacêutica e usos dos referidos compostos
EP3141252B8 (en) 2009-06-17 2019-03-13 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP2613781B1 (en) * 2010-09-08 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Indazole derivatives for use in the treatment of influenza virus infection
RU2013132681A (ru) * 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
AU2011343647A1 (en) * 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UA118010C2 (uk) * 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP2763990B1 (en) 2011-09-01 2017-02-22 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
EP2858984A1 (en) * 2012-06-08 2015-04-15 Vertex Pharmaceuticals Inc. Inhibitors of influenza viruses replication
EP3578554A1 (en) 2013-11-13 2019-12-11 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3177609A1 (en) 2014-08-08 2017-06-14 Janssen Sciences Ireland UC Indoles for use in influenza virus infection
UY36249A (es) 2014-08-08 2016-01-29 Bayer Cropscience Ag Compuestos sustituidos con halógeno novedosos
UY36255A (es) 2014-08-08 2016-01-29 Bayer Cropscience Ag Compuestos sustituidos por halógeno novedosos
CN104592038A (zh) 2015-01-12 2015-05-06 烟台万润精细化工股份有限公司 一种5,5-二甲基-1,3-环己二胺的制备方法

Also Published As

Publication number Publication date
MX2017001752A (es) 2018-02-08
CN106573920A (zh) 2017-04-19
AU2015298876B2 (en) 2020-02-13
AU2015298876A1 (en) 2017-02-02
BR112017002370B1 (pt) 2022-11-22
CA2954751C (en) 2023-01-17
KR20170039275A (ko) 2017-04-10
JP6577570B2 (ja) 2019-09-18
CA2954751A1 (en) 2016-02-11
IL250408B (en) 2020-08-31
SG11201700956VA (en) 2017-03-30
EP3177609A1 (en) 2017-06-14
JP2017523225A (ja) 2017-08-17
PH12017500207A1 (en) 2017-07-10
US20170226102A1 (en) 2017-08-10
ZA201700952B (en) 2018-12-19
US10597390B2 (en) 2020-03-24
UA124609C2 (uk) 2021-10-20
KR102488479B1 (ko) 2023-01-12
MA40547A (fr) 2017-06-14
EA201790266A1 (ru) 2017-06-30
IL250408A0 (en) 2017-03-30
BR112017002370A2 (pt) 2017-12-05
CN106573920B (zh) 2020-11-10
PH12017500207B1 (en) 2017-07-10
WO2016020526A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
CL2017000309A1 (es) Indoles para su uso en la infección por el virus de la gripe
CL2017000533A1 (es) Pirrolopirimidinas para uso en la infección por el virus de la gripe
CL2018001960A1 (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza.
CL2016001120A1 (es) Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct
UY37252A (es) Compuestos para el tratamiento de infección por virus de la hepatitis b
CL2016000424A1 (es) Métodos y composiciones para el arn-guiado tratamiento de la infección por vih
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
CL2014001956A1 (es) Compuestos derivados de beta-lactamicos sustituidos con amidina; metodo para su preparacion; medicamento que los comprende; y su uso para el tratamiento y/o profilaxis de infecciones bacterianas.
CR20150337A (es) Derivados de pirimidinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2015003615A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
CL2015002335A1 (es) Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas.
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
CR20160499A (es) Composiciones estables de yodo no en complejo y métodos de uso
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2017000152A1 (es) Derivados de isoindolinona
EA201891576A1 (ru) Функционализированные пентановые кислоты для применения при инфекциях, вызванных вирусом гриппа
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2017001209A1 (es) Inhibidor de cinasa aurora a
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CL2017000151A1 (es) Derivados de piridona
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
EA201690594A1 (ru) Состав для лечения вич-инфекции на основе атазанавира и кобицистата